ABSTRACT

Type 2 diabetes mellitus is the most common form of diabetes comprising 80% of all diabetic population. The World Health Organization has predicted that developing countries would have to bear the major burden of this disease. It has been estimated that there will be a 42% increase from 51 to 72 million individuals affected in the developed countries. In developing countries these figures are much higher and are expected to show 170% increase from 84 to 228 million [1,2]. The long term consequences of type 2 diabetes make it imperative to focus on the development of novel treatment strategies for the management of insulin resistance and the metabolic syndrome.